Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

JAMA. 2019 May 7;321(17):1720-1721. doi: 10.1001/jama.2019.2702.
No abstract available

Publication types

  • Corrected and Republished Article